Eliem Therapeutics Alpha and Beta Analysis
| ELYMDelisted Stock | USD 3.00 0.09 2.91% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Eliem Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Eliem Therapeutics over a specified time horizon. Remember, high Eliem Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Eliem Therapeutics' market risk premium analysis include:
Beta (1.27) | Alpha (0.78) | Risk 5.49 | Sharpe Ratio (0.18) | Expected Return (1.01) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Eliem |
Eliem Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Eliem Therapeutics market risk premium is the additional return an investor will receive from holding Eliem Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Eliem Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Eliem Therapeutics' performance over market.| α | -0.78 | β | -1.27 |
Eliem Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Eliem Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Eliem Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Eliem Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Eliem Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Eliem Therapeutics shares will generate the highest return on investment. By understating and applying Eliem Therapeutics stock market price indicators, traders can identify Eliem Therapeutics position entry and exit signals to maximize returns.
Eliem Therapeutics Return and Market Media
The median price of Eliem Therapeutics for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 5.14 with a coefficient of variation of 30.04. The daily time series for the period is distributed with a sample standard deviation of 1.63, arithmetic mean of 5.43, and mean deviation of 1.34. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit | 09/11/2024 |
2 | Disposition of tradable shares by Emily Pimblett of Eliem Therapeutics at 8.06 subject to Rule 16b-3 | 09/20/2024 |
3 | 500,000 Shares in Eliem Therapeutics, Inc. Acquired by Ally Bridge Group NY LLC - MarketBeat | 09/24/2024 |
4 | ELYM Stock Earnings Eliem Therapeutics Reported Results for Q4 2023 - MSN | 11/20/2024 |
About Eliem Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Eliem or other delisted stocks. Alpha measures the amount that position in Eliem Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Eliem Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Eliem Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Eliem Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Eliem Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Eliem Therapeutics. Please utilize our Beneish M Score to check the likelihood of Eliem Therapeutics' management manipulating its earnings.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Eliem Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Eliem Therapeutics Backtesting, Eliem Therapeutics Valuation, Eliem Therapeutics Correlation, Eliem Therapeutics Hype Analysis, Eliem Therapeutics Volatility, Eliem Therapeutics History and analyze Eliem Therapeutics Performance. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Global Correlations Find global opportunities by holding instruments from different markets |